{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:16:46Z","timestamp":1790957806072,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009700","name":"Fondazione Gigi e Pupa Ferrari ONLUS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.phrs.2018.08.020","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T14:06:45Z","timestamp":1535119605000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-5300","authenticated-orcid":false,"given":"Veronika A.","family":"Myasoedova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio L.","family":"Ravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Songia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7225-3379","authenticated-orcid":false,"given":"Paolo","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/CIRCINTERVENTIONS.112.971028","article-title":"Cellular mechanisms of aortic valve calcification","volume":"5","author":"Leopold","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2014.11.026","article-title":"Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET\/CT study","volume":"238","author":"Abdelbaky","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cjp2.21","article-title":"The pathology and pathobiology of bicuspid aortic valve: state of the art and novel research perspectives","volume":"1","author":"Mathieu","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"issue":"9","key":"10.1016\/j.phrs.2018.08.020_bib0020","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.95.9.2262","article-title":"Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome","volume":"95","author":"Otto","year":"1997","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.phrs.2018.08.020_bib0025","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","article-title":"Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies","volume":"111","author":"Freeman","year":"2005","journal-title":"Circulation"},{"issue":"9540","key":"10.1016\/j.phrs.2018.08.020_bib0030","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0035","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/heartjnl-2012-302265","article-title":"The evolving epidemiology of valvular aortic stenosis. The Tromso Study","volume":"99","author":"Eveborn","year":"2013","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0149-936X(81)90030-8","article-title":"Thickened renal fascia--a sign of retroperitoneal pathology","volume":"5","author":"Hadar","year":"1981","journal-title":"J. Comput. Tomogr."},{"key":"10.1016\/j.phrs.2018.08.020_bib0045","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MED.0000000000000237","article-title":"Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk","volume":"23","author":"Tsimikas","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrcardio.2014.1","article-title":"Potential drug targets for calcific aortic valve disease","volume":"11","author":"Hutcheson","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"17","key":"10.1016\/j.phrs.2018.08.020_bib0060","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2014.13959","article-title":"Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis","volume":"312","author":"Smith","year":"2014","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.phrs.2018.08.020_bib0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.2010.215046","article-title":"Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?","volume":"97","author":"Parolari","year":"2011","journal-title":"Heart"},{"issue":"Suppl. 9","key":"10.1016\/j.phrs.2018.08.020_bib0070","first-page":"I229","article-title":"Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway","volume":"112","author":"Rajamannan","year":"2005","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.phrs.2018.08.020_bib0075","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2008.04.060","article-title":"Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg)","volume":"102","author":"Dichtl","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"13","key":"10.1016\/j.phrs.2018.08.020_bib0085","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2018.08.020_bib0090","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2018.08.020_bib0100","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.amjcard.2010.07.042","article-title":"Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study)","volume":"106","author":"Gerdts","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0105","first-page":"337","article-title":"The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality","volume":"21","author":"Ardehali","year":"2012","journal-title":"J. Heart Valve Dis."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.90.2.844","article-title":"Characterization of the early lesion of\u2019 degenerative\u2019 valvular aortic stenosis. Histological and immunohistochemical studies","volume":"90","author":"Otto","year":"1994","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0115","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejcts.2008.11.033","article-title":"Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention","volume":"35","author":"Parolari","year":"2009","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3949\/ccjm.70.5.471","article-title":"Calcific aortic stenosis: another face of atherosclerosis?","volume":"70","author":"Novaro","year":"2003","journal-title":"Cleve. Clin. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/heart.85.6.601","article-title":"Why is there discordance between calcific aortic stenosis and coronary artery disease?","volume":"85","author":"Otto","year":"2001","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.phrs.2018.08.020_bib0135","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/cvr\/cvx089","article-title":"OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-kappaB pathway","volume":"113","author":"Nsaibia","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.phrs.2018.08.020_bib0140","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/hrt.2007.125740","article-title":"Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis","volume":"94","author":"Cote","year":"2008","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization","volume":"63","author":"Mahmut","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0150","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.08.020_bib0160","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.117.032291","article-title":"Spatiotemporal multi-omics mapping generates a molecular atlas of the aortic valve and reveals networks driving disease","author":"Schlotter","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J. Intern. Med."},{"issue":"23","key":"10.1016\/j.phrs.2018.08.020_bib0170","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2018.08.020_bib0175","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-017-6721-6","article-title":"Raloxifene lowers plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials","author":"Ferretti","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0180","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0185","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"10","key":"10.1016\/j.phrs.2018.08.020_bib0190","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11883-013-0360-6","article-title":"Update on lipoprotein(a) as a cardiovascular risk factor and mediator","volume":"15","author":"Boffa","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2018.08.020_bib0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.115.018139","article-title":"A not-so-little role for lipoprotein(a) in the development of calcific aortic valve disease","volume":"132","author":"Rogers","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvq052","article-title":"Autotaxin--an LPA producing enzyme with diverse functions","volume":"148","author":"Nakanaga","year":"2010","journal-title":"J. Biochem."},{"issue":"12","key":"10.1016\/j.phrs.2018.08.020_bib0205","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0002-9149(99)80263-X","article-title":"Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study)","volume":"76","author":"Gotoh","year":"1995","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0210","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0215","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0220","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2018.08.020_bib0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-016-0622-1","article-title":"Emerging therapeutic options for lowering of lipoprotein(a): implications for prevention of cardiovascular disease","volume":"18","author":"Boffa","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2018.08.020_bib0230","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10002","key":"10.1016\/j.phrs.2018.08.020_bib0235","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0240","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1194\/jlr.R052258","article-title":"Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans","volume":"57","author":"Graham","year":"2016","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"13","key":"10.1016\/j.phrs.2018.08.020_bib0250","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10557-016-6654-5","article-title":"Future directions to establish lipoprotein(a) as a treatment for atherosclerotic cardiovascular disease","volume":"30","author":"Stein","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"11","key":"10.1016\/j.phrs.2018.08.020_bib0260","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.amjmed.2016.07.038","article-title":"Role of niacin in current clinical practice: a systematic review","volume":"130","author":"Garg","year":"2017","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0270","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2003.11.011","article-title":"Lipid profile of patients with aortic stenosis might be predictive of rate of progression","volume":"147","author":"Yilmaz","year":"2004","journal-title":"Am. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0275","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/bjp.2008.122","article-title":"Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits","volume":"154","author":"Busseuil","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2018.08.020_bib0280","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/bph.12236","article-title":"Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice","volume":"169","author":"Trapeaux","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.phrs.2018.08.020_bib0285","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/eurheartj\/ehq064","article-title":"Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model","volume":"31","author":"Speidl","year":"2010","journal-title":"Eur. Heart J."},{"issue":"24","key":"10.1016\/j.phrs.2018.08.020_bib0290","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.phrs.2018.08.020_bib0295","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis intervention in metabolic syndrome with low HDL\/High triglyceride and impact on global health outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0300","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2018.08.020_bib0305","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart diseas","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0310","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics - a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0315","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor\u2019s role","volume":"57","author":"Raal","year":"2016","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0320","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jacc.2004.03.061","article-title":"Is it ever too late to operate on the patient with valvular heart disease?","volume":"44","author":"Carabello","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.08.020_bib0325","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2018.08.020_bib0330","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-Function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0335","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0300060516648030","article-title":"Proprotein convertase subtilisin\/kexin type 9 levels and aortic valve calcification: a prospective, cross sectional study","volume":"44","author":"Wang","year":"2016","journal-title":"J. Int. Med. Res."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0340","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10753-012-9579-6","article-title":"Inflammation is associated with the remodeling of calcific aortic valve disease","volume":"36","author":"Cote","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2018.08.020_bib0345","doi-asserted-by":"crossref","first-page":"685926","DOI":"10.4061\/2010\/685926","article-title":"Crystalline ultrastructures, inflammatory elements, and neoangiogenesis are present in inconspicuous aortic valve tissue","volume":"2010","author":"Dorfmuller","year":"2010","journal-title":"Cardiol. Res. Pract."},{"issue":"16","key":"10.1016\/j.phrs.2018.08.020_bib0350","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/eurheartj\/ehq237","article-title":"Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation","volume":"31","author":"Hjortnaes","year":"2010","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0355","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0360","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J. Pathol."},{"issue":"1-2","key":"10.1016\/j.phrs.2018.08.020_bib0365","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cca.2011.09.023","article-title":"Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration","volume":"413","author":"Miyazawa","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0370","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2007.03.040","article-title":"Complement system is activated in stenotic aortic valves","volume":"196","author":"Helske","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2018.08.020_bib0375","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yjmcc.2015.03.002","article-title":"Carbonic anhydrase XII in valve interstitial cells promotes the regression of calcific aortic valve stenosis","volume":"82","author":"Bouchareb","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"20","key":"10.1016\/j.phrs.2018.08.020_bib0380","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1161\/CIRCULATIONAHA.108.834614","article-title":"Lowering plasma cholesterol levels halts progression of aortic valve disease in mice","volume":"119","author":"Miller","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.08.020_bib0385","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yjmcc.2014.02.014","article-title":"P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease","volume":"72","author":"El Husseini","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0390","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14756360410001689540","article-title":"Carbonic anhydrases: current state of the art, therapeutic applications and future prospects","volume":"19","author":"Pastorekova","year":"2004","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0395","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbrc.2013.10.003","article-title":"CD34-negative mesenchymal stem-like cells may act as the cellular origin of human aortic valve calcification","volume":"440","author":"Nomura","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0400","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jss.2013.05.001","article-title":"ox-LDL induces PiT-1 expression in human aortic valve interstitial cells","volume":"184","author":"Nadlonek","year":"2013","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0405","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jphs.2016.04.013","article-title":"1-Methyl-2-undecyl-4(1H)-quinolone, a derivative of quinolone alkaloid evocarpine, attenuates high phosphate-induced calcification of human aortic valve interstitial cells by inhibiting phosphate cotransporter PiT-1","volume":"131","author":"Seya","year":"2016","journal-title":"J. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jjcc.2015.05.004","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery","volume":"66","author":"Ivanova","year":"2015","journal-title":"J. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2018.08.020_bib0415","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0420","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00395-012-0306-0","article-title":"Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products","volume":"107","author":"Li","year":"2012","journal-title":"Basic Res. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.08.020_bib0425","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/ATVBAHA.112.300794","article-title":"Pioglitazone attenuates valvular calcification induced by hypercholesterolemia","volume":"33","author":"Chu","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0430","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1210\/jc.2007-0328","article-title":"Thiazolidinediones: new evidence of bone loss","volume":"92","author":"Schwartz","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2018.08.020_bib0435","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","article-title":"Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis","volume":"298","author":"Singh","year":"2007","journal-title":"Jama"},{"issue":"16","key":"10.1016\/j.phrs.2018.08.020_bib0440","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","article-title":"Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation","volume":"121","author":"Kaul","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0445","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X162746","article-title":"Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"21","key":"10.1016\/j.phrs.2018.08.020_bib0450","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0455","doi-asserted-by":"crossref","first-page":"H1454","DOI":"10.1152\/ajpheart.00867.2009","article-title":"The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA","volume":"298","author":"Ye","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.08.020_bib0460","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease","volume":"123","author":"Isik","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"44","key":"10.1016\/j.phrs.2018.08.020_bib0465","doi-asserted-by":"crossref","first-page":"77168","DOI":"10.18632\/oncotarget.20417","article-title":"Sitagliptin attenuates high glucose-induced alterations in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells through ERK1\/2 signal pathway","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.phrs.2018.08.020_bib0470","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/CIRCULATIONAHA.116.024270","article-title":"Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells","volume":"135","author":"Choi","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2018.08.020_bib0475","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0003-4975(02)04312-6","article-title":"Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis","volume":"75","author":"Jian","year":"2003","journal-title":"Ann. Thorac. Surg."},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0480","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.carpath.2007.03.006","article-title":"Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast","volume":"16","author":"Merryman","year":"2007","journal-title":"Cardiovasc. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2018.08.020_bib0485","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"23","key":"10.1016\/j.phrs.2018.08.020_bib0490","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0495","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.yjmcc.2012.08.012","article-title":"5-HT(2B) antagonism arrests non-canonical TGF-beta1-induced valvular myofibroblast differentiation","volume":"53","author":"Hutcheson","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0500","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/ATVBAHA.112.300278","article-title":"Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts","volume":"33","author":"Hutcheson","year":"2013","journal-title":"Arteriosclerosis Thrombosis Vasc. Boil."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ydbio.2015.07.012","article-title":"Cadherin-11 coordinates cellular migration and extracellular matrix remodeling during aortic valve maturation","volume":"407","author":"Bowen","year":"2015","journal-title":"Dev. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2018.08.020_bib0510","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/ATVBAHA.114.305095","article-title":"Notch1 Mutation Leads to Valvular Calcification Through Enhanced Myofibroblast Mechanotransduction","volume":"35","author":"Chen","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"24","key":"10.1016\/j.phrs.2018.08.020_bib0515","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1161\/CIRCULATIONAHA.117.027771","article-title":"Targeting cadherin-11 prevents Notch1-mediated calcific aortic valve disease","volume":"135","author":"Clark","year":"2017","journal-title":"Circulation."},{"issue":"7056","key":"10.1016\/j.phrs.2018.08.020_bib0520","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature03940","article-title":"Mutations in NOTCH1 cause aortic valve disease","volume":"437","author":"Garg","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0525","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCRESAHA.110.221358","article-title":"Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model","volume":"107","author":"Hinton","year":"2010","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.phrs.2018.08.020_bib0530","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1161\/01.ATV.0000228824.01604.63","article-title":"Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves","volume":"26","author":"Helske","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"13","key":"10.1016\/j.phrs.2018.08.020_bib0535","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1161\/CIRCULATIONAHA.108.827972","article-title":"Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease","volume":"119","author":"Aikawa","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2018.08.020_bib0540","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.ATV.19.5.1218","article-title":"Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves","volume":"19","author":"Olsson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0545","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"issue":"8","key":"10.1016\/j.phrs.2018.08.020_bib0550","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2174\/1381612823666161123144534","article-title":"antihypertensive treatments in patients affected by aortic valve stenosis","volume":"23","author":"Poggio","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2018.08.020_bib0555","first-page":"61","article-title":"Aortic stenosis","volume":"38","author":"Ross","year":"1968","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0560","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.109.894170","article-title":"Natural history of very severe aortic stenosis","volume":"121","author":"Rosenhek","year":"2010","journal-title":"Circulation."},{"key":"10.1016\/j.phrs.2018.08.020_bib0565","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fcvm.2018.00092","article-title":"Expanding TAVI to Low and intermediate risk patients","volume":"5","author":"Voigtlander","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0570","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15420\/icr.2016:24:2","article-title":"A glimpse into the future: in 2020, which patients will undergo TAVI or SAVR?","volume":"12","author":"O\u2019Sullivan","year":"2017","journal-title":"Interv. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2018.08.020_bib0575","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the Copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arteriosclerosis Thrombosis Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2018.08.020_bib0580","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2014.09.016","article-title":"Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study","volume":"8","author":"Capoulade","year":"2015","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"4","key":"10.1016\/j.phrs.2018.08.020_bib0585","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of\u2019 degenerative\u2019 valvular aortic stenosis","volume":"16","author":"O\u2019Brien","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818310764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818310764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T19:10:23Z","timestamp":1571771423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818310764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":117,"alternative-id":["S1043661818310764"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.08.020","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}